KR102752714B1 - 그렐린 수용체 작용제로서의 트리아졸 화합물의 용도 - Google Patents

그렐린 수용체 작용제로서의 트리아졸 화합물의 용도 Download PDF

Info

Publication number
KR102752714B1
KR102752714B1 KR1020210125105A KR20210125105A KR102752714B1 KR 102752714 B1 KR102752714 B1 KR 102752714B1 KR 1020210125105 A KR1020210125105 A KR 1020210125105A KR 20210125105 A KR20210125105 A KR 20210125105A KR 102752714 B1 KR102752714 B1 KR 102752714B1
Authority
KR
South Korea
Prior art keywords
ghrelin receptor
compound
chemical formula
ghrelin
cachexia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020210125105A
Other languages
English (en)
Korean (ko)
Other versions
KR20220039625A (ko
Inventor
배재성
진희경
박민희
Original Assignee
경북대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 경북대학교 산학협력단 filed Critical 경북대학교 산학협력단
Publication of KR20220039625A publication Critical patent/KR20220039625A/ko
Application granted granted Critical
Publication of KR102752714B1 publication Critical patent/KR102752714B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020210125105A 2020-09-22 2021-09-17 그렐린 수용체 작용제로서의 트리아졸 화합물의 용도 Active KR102752714B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200122540 2020-09-22
KR1020200122540 2020-09-22

Publications (2)

Publication Number Publication Date
KR20220039625A KR20220039625A (ko) 2022-03-29
KR102752714B1 true KR102752714B1 (ko) 2025-01-10

Family

ID=80845629

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020210125105A Active KR102752714B1 (ko) 2020-09-22 2021-09-17 그렐린 수용체 작용제로서의 트리아졸 화합물의 용도

Country Status (6)

Country Link
US (1) US12570617B2 (https=)
EP (1) EP4218757A4 (https=)
JP (1) JP7799262B2 (https=)
KR (1) KR102752714B1 (https=)
CN (2) CN116669575B (https=)
WO (1) WO2022065831A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022448086B2 (en) * 2022-03-23 2024-02-01 Nextgen Bioscience Co., Ltd. Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for s1pr1 and s1pr4

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102017324B1 (ko) 2018-04-30 2019-09-02 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
ES2388501T3 (es) * 2004-08-12 2012-10-16 Helsinn Healthcare S.A. Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal
US10975070B2 (en) * 2010-02-26 2021-04-13 Raqualia Pharma Inc. Ghrelin receptor agonist for treatment of cachexia
EP2431035A1 (en) * 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
KR20150020602A (ko) * 2012-05-25 2015-02-26 라퀄리아 파마 인코포레이티드 무산증 치료를 위한 그렐린 수용체 효능물질
ES2864079T3 (es) * 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2017075535A1 (en) * 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
KR101830244B1 (ko) * 2016-01-20 2018-02-21 서울대학교 산학협력단 신규한 헤테로방향족 고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 s1p 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
KR20180036318A (ko) 2016-09-30 2018-04-09 경북대학교 산학협력단 2-아미노-2-(1-도데실-1h-1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체를 유효성분으로 포함하는 퇴행성 신경질환 및 우울증 예방 또는 치료용 약학적 조성물
KR102292989B1 (ko) 2017-03-29 2021-08-26 재단법인 아산사회복지재단 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
KR102609693B1 (ko) 2019-04-18 2023-12-05 현대모비스 주식회사 차량의 전원 백업 장치

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102017324B1 (ko) 2018-04-30 2019-09-02 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도

Also Published As

Publication number Publication date
CN116669575A (zh) 2023-08-29
EP4218757A1 (en) 2023-08-02
CN116669575B (zh) 2025-04-04
JP7799262B2 (ja) 2026-01-15
US12570617B2 (en) 2026-03-10
US20230339869A1 (en) 2023-10-26
WO2022065831A1 (ko) 2022-03-31
JP2023542964A (ja) 2023-10-12
CN120081796A (zh) 2025-06-03
EP4218757A4 (en) 2024-11-13
KR20220039625A (ko) 2022-03-29

Similar Documents

Publication Publication Date Title
TWI603967B (zh) 具有增進之受體活性及生物有效性性質之新穎三唑衍生物在用作生長激素促泌素受體之腦腸肽拮抗劑上之用途
EA018894B1 (ru) N,n-диметил-5-(2-метил-6-((5-метилпиразин-2-ил)карбамоил)бензо-фуран-4-илокси)пиримидин-2-карбоксамид, используемый в качестве активатора глюкокиназы, и содержащая его фармацев-тическая композиция
WO2013087004A1 (zh) 咪唑二酮类化合物及其用途
EA009199B1 (ru) N-мостиковые селективные модуляторы андрогенных рецепторов и способы их применения
AU2006281594A1 (en) Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
WO2009107660A1 (ja) 糖尿病又は肥満病の予防又は治療剤
KR101924737B1 (ko) 페루로일티라민 화합물을 포함하는 stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도
KR102752714B1 (ko) 그렐린 수용체 작용제로서의 트리아졸 화합물의 용도
CN106170485B (zh) 对位取代的不对称脲及其医疗用途
JP6910188B2 (ja) Ｔｒｐａ１活性化剤
US20090018161A1 (en) Method for promoting gastrointestinal function and method for screening for promoter of gastrointestinal function
JP5599519B2 (ja) キノリン誘導体化合物、その製造方法およびそれを含む薬学組成物
CN114302881B (zh) 适用于治疗和预防肌肉萎缩和其他状况的化合物
JP2022065014A (ja) 重水素化イミダゾリジンジオン化合物とその用途
WO2013073698A1 (ja) Cxcr4活性阻害ペプチド及びその用途
JP6496599B2 (ja) 筋タンパク質合成シグナル活性化剤
EP2263666A1 (en) Agent and food for prevention/amelioration of functional gastrointestinal disorders
EA034427B1 (ru) Производные индола
JP5158779B2 (ja) Ｄ−アロースを有効成分とする血圧上昇抑制剤
JP7185226B2 (ja) １，５－アンヒドロフルクトース誘導体を含むａｍｐｋ活性化剤
KR102114197B1 (ko) 신규한 벤질리덴아세톤 유도체 및 이의 용도
CN110996930A (zh) 新型亚苄基丙酮衍生物及其用途
WO2014074700A1 (en) Antagonists of gpr119 receptor and the treatment of disorders related thereto
JP4790803B2 (ja) 化合物、α１アドレナリン受容体拮抗剤、及び組成物
KR20230061281A (ko) 안지오텐신 수용체 차단제 및 sglt2 억제제를 포함하는 복합 조성물

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000